Acetylation occurs on numerous metabolic enzymes and regulates their activities in mammals and bacteria (24, 25) . Given that succinylCoA and malonyl-CoA are common metabolites like acetyl-CoA (14) , and all the succinylated and malonylated proteins we found are metabolic enzymes, it is likely that protein lysine succinylation and malonylation function similarly to acetylation and regulate metabolism (24, 25) . 1 Steven G. Kinsey, 4 Maria Cecilia G. Marcondes, 3 Anna M. Ward, 1 Yun Kyung Hahn, 5 Aron H. Lichtman, 5 Bruno Conti, 3 Benjamin F. Cravatt 1 * † Phospholipase A 2 (PLA 2 ) enzymes are considered the primary source of arachidonic acid for cyclooxygenase (COX)-mediated biosynthesis of prostaglandins. Here, we show that a distinct pathway exists in brain, where monoacylglycerol lipase (MAGL) hydrolyzes the endocannabinoid 2-arachidonoylglycerol to generate a major arachidonate precursor pool for neuroinflammatory prostaglandins. MAGL-disrupted animals show neuroprotection in a parkinsonian mouse model. These animals are spared the hemorrhaging caused by COX inhibitors in the gut, where prostaglandins are instead regulated by cytosolic PLA 2 . These findings identify MAGL as a distinct metabolic node that couples endocannabinoid to prostaglandin signaling networks in the nervous system and suggest that inhibition of this enzyme may be a new and potentially safer way to suppress the proinflammatory cascades that underlie neurodegenerative disorders.
I
nflammation is a hallmark of many neurological disorders, including chronic pain, traumatic brain injury, neurodegenerative diseases, and stroke (1) . Prominent among the known proinflammatory stimuli in the nervous system are prostaglandins, which are produced by cyclooxygenase enzymes (COX1 and COX2) (2) that are in neurons and glial cells (3) . Rodents treated with COX inhibitors or lacking COX enzymes show protection in models of neurodegenerative disorders that have an inflammatory component such as Parkinson's and Alzheimer's disease (4) (5) (6) . However, the gastrointestinal and cardiovascular toxicities displayed by COX inhibitors have limited their translational potential for neuroinflammatory syndromes (7, 8) . Phospholipase A 2 (PLA 2 ) enzymes, and cytosolic PLA 2 (cPLA 2 or Pla2g4a) in particular, have been viewed as the principal source of Table 1 . The kinetic parameters of Sirt5 on acetyl, malonyl, and succinyl peptides with different sequences. ND, cannot be determined either because no activity was observed or because initial rate (V) versus substrate concentration ([S]) was linear (even the highest [S] of 750 mM used was much smaller than the K m ). (16) . Similar results were obtained with mice killed by head-focused microwave irradiation, although the absolute brain levels of AA and prostaglandins in these animals were 1/5th to 1/20th those of the decapitated mice. (fig. S2) (17) . Data are means T SEM; N = 4 to 5 mice per group. Experiments were performed twice, and one data set is shown. arachidonic acid (AA) for COX-mediated prostaglandin production (9); however, cPLA 2 -deficient mice have unaltered AA levels in brain (10) . This finding, coupled with our recent observation that the genetic or pharmacological inactivation of monoacylglycerol lipase (MAGL, Mgll) in mice causes significant reductions in brain AA (11) (12) (13) , led us to investigate the potential existence of non-PLA 2 mechanisms that regulate prostaglandin production in the nervous system. MAGL has been studied mostly for its role in hydrolyzing the endocannabinoid 2-arachidonoylglycerol (2-AG) (11, 14, 15) . Consistent with previous investigations, we found that mice deficient in the gene that encodes MAGL (Mgll -/-mice) or mice treated with the MAGLselective inhibitor JZL184 [40 mg/kg, intraperitoneally (i.p.)] showed loss of MAGL activity (11, 12) , but not other brain serine hydrolase activities ( fig. S1, A and B) , and had elevated brain levels of 2-AG and corresponding reductions in AA (Fig. 1 , A to C) (16) (table S1). We more broadly profiled the metabolomic effects of MAGL disruption, using a combination of targeted and untargeted metabolomic approaches, and discovered by targeted analysis that inactivation of this enzyme also caused significant reductions in several prostaglandins and other eicosanoids in the brain, including prostaglandin E 2 (PGE 2 ), PGD 2 , PGF 2 , and thromboxane B2 (TXB2) (Fig. 1 , A to C, and fig. S2A ) (17) . In contrast, other arachidonoylcontaining phospho-and neutral lipid speciesincluding the second major endocannabinoid anandamide (N-arachidonoylethanolamide), as well as other free fatty acids-were unaltered in brain tissue from MAGL-deficient animals ( Fig. 1, A to C, and fig. S3 ). These results indicate that the principal metabolic effects of disrupting MAGL in the brain are elevations in substrate MAGs, including 2-AG, and reductions in the product AA and downstream AAderived eicosanoids.
We next asked whether MAGL also controls eicosanoid production in states of neuroinflammation. Mice were systemically administered the proinflammatory agent lipopolysaccharide (LPS) (18) (20 mg/kg i.p.) for 2 to 6 hours, then animals were killed and their brain lipids measured. LPS treatment produced a robust, time-dependent increase in brain eicosanoids (Fig. 1, B and C, and  fig. S2 , A and C), and these changes were markedly blunted in mice treated with JZL184 (Fig.  1B and fig. S2A ) and in Mgll -/-mice ( Fig. 1C and  fig. S2A ). Eicosanoids did rise substantially in brains from LPS-treated mice lacking MAGL; however, their levels did not significantly exceed the basal levels observed in untreated wild-type mice (Fig. 1, B fig. S4B) , which strengthened our conclusion that this metabolic effect is a direct consequence of reductions in AA rather than an indirect consequence of enhanced endocannabinoid signaling. COX1-selective (by SC560), but not COX2-selective (by celecoxib) inhibition, reduced both basal and LPS-induced brain prostaglandin levels, which mirrored the metabolic effects caused by MAGL inactivation (fig. S4C) . We also noted that LPS treatment did not alter brain AA levels, despite causing elevations in prostaglandins. This finding could be explained in the context of previous reports showing that LPS induces COX1 expression in the brain (19) . A model thus emerges where LPS-induced COX1 shunts a small proportion of the high bulk levels of AA (20 to 100 nmol/g brain weight) toward prostaglandins, which are found at much lower levels in brain (1 to 100 pmol/g brain weight). By controlling the quantity of AA available to LPSinduced COX1, MAGL exerts a crucial control over brain prostaglandin production in both basal and neuroinflammatory states.
LPS treatment induces widespread elevations in proinflammatory cytokines, including interleukin-1a (IL-1a), IL-1b, IL-6, and tumor necrosis factor a (TNFa) (20) . We found that pharmacological or genetic inactivation of MAGL, although not affecting basal cytokine levels, produced a near-complete blockade of LPSinduced elevations in brain cytokines ( Fig. 2A  and fig. S5A ). This suppression of cytokines was not reversed by CB1 or CB2 antagonists or in Cnr1/Cnr2 -/-mice ( Fig. 2A and fig. S5B ). Disruption of MAGL also blocked LPS-induced microglial activation (Fig. 2B and fig. S5, C and  D) . SC-560 also reduced LPS-stimulated cytokine production in the brain, whereas celecoxib paradoxically further increased IL-1a and IL-1b levels in LPS-treated animals ( fig. S6) . These results are consistent with recent studies showing that mice deficient in COX1 and COX2 display attenuated and exacerbated neuroinflammatory responses to LPS-treatment, respectively (2, 20, 21) .
Because previous studies have provided evidence that cPLA 2 also plays a role in prostaglandin production and neuroinflammation (10, (22) (23) (24) , we sought to assess the relative contributions of MAGL and cPLA 2 to brain prostaglandin generation. As has been reported previously (10, 22) , we found that the basal levels of AA and prostaglandins-as well as general serine hydrolase activities, including MAGLwere unaltered in brain tissue from mice deficient in cPLA 2 (Pla2g4a -/-mice) (25) (Fig. 3A  and fig. S7, A and B) . A modest, but significant, reduction (~20%) in LPS-induced prostaglandins was, however, detected in brains from Pla2g4a -/-mice (Fig. 3A) , consistent with past findings (22) . This reduction in brain prostaglandins was much lower in magnitude than the decrease observed in MAGL-deficient animals. Note that the effects of MAGL and cPLA 2 blockade were additive: Treatment with JZL184 produced greater reductions in brain prostaglandins in LPS-treated Pla2g4a -/-mice than in LPS-treated Pla2g4a +/+ mice (Fig. 3A) . These data indicate that both MAGL and cPLA 2 contribute to the AA pools for neuroinflammatory prostaglandins, such that the combined inactivation of these enzymes completely blocks brain prostaglandin increases caused by LPS.
Intrigued by the different roles played by MAGL and cPLA 2 in the brain, we expanded our analysis of these enzymes' contributions to prostaglandin metabolism to peripheral tissues. A clear partitioning of function was uncovered, with MAGL exerting control over both basal and LPS-induced AA and prostaglandins in liver and lung (Fig. 3 , B and C), whereas cPLA 2 dopamine levels eicosanoids regulated these lipids in gut and spleen (Fig. 3, D and E). We also found that elevations in proinflammatory cytokines were significantly blunted in lung and liver tissue from LPS-treated Mgll -/-mice ( fig. S8, A and B) . Neither MAGL nor cPLA 2 made a substantial contribution to prostaglandin production in heart or kidney ( fig. S8, C and D) , where distinct PLA 2 s (26) may regulate eicosanoid metabolic pathways. These findings reveal a clear anatomical segregation for the enzymatic pathways that supply the AA precursor of proinflammatory prostaglandins, and further, they suggest that MAGL inactivation may avoid some of the major adverse pharmacological effects of COX inhibitors (7) . Prominent among the toxicities caused by COX inhibitors is gastrointestinal bleeding (7). Consistent with our finding, JZL184 does not cause the gastric hemorrhaging that is observed with COX1 or dual COX inhibitors ( fig. S9) . On the contrary, recent data suggest that inhibition of MAGL by JZL184 exerts a CB1 receptor-dependent protective effect on COX inhibitor-induced gastric bleeding (27) . Many neurodegenerative disorders involve a strong inflammatory component (1) . We tested the effects of MAGL blockade in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinsonism, in which COX inhibitors are known to be neuroprotective (4). Indeed, neuroprotection could be partly due to blocking PGE 2 production, which is toxic to dopaminergic neurons (28) . We found that either pharmacologic (JZL184, 40 mg/kg, oral treatment once per day starting 24 hours before MPTP treatment) or genetic inactivation of MAGL prevented MPTPinduced dopaminergic neuronal loss in the substantia nigra (Fig. 4, A and B, and fig. S10 , A and B) and significantly attenuated dopaminergic neuronal terminal loss ( fig. S10C ) and dopamine reductions in both the substantia nigra and striatum (Fig. 4C and fig. S10D ). These neuroprotective effects were accompanied by a blockade of MPTP-induced increases in brain AA, prostaglandins (Fig. 4D and fig. S10E ), and proinflammatory cytokines ( fig. S10F ). MPTP treatment also led to elevations in brain 2-AG, which is a likely source for the MAGL-dependent increases in AA and prostaglandins ( fig. S10G ). Although cannabinoid agonists have previously been shown to protect against neurodegeneration in the MPTP model (29) , the effects of MAGL blockade were not reversed by cannabinoid receptor antagonists (Fig. 4, A to C, and fig. S10H ), and were recapitulated by COX inhibition (fig.  S10 ). Pharmacological or genetic disruption of MAGL did not affect the metabolism of MPTP to 1-methyl-4-phenylpyridinium (MPP+) (fig. S11). We conclude that the neuroprotective effects of MAGL inactivation are primarily due to reductions in AA and proinflammatory prostaglandins rather than augmentation of endocannabinoid signaling.
Mammals have multiple COX enzymes (COX1 and COX2) (3) that produce prostaglandins, and the functional characterization and selective targeting of these enzymes have led to drugs for treating pain disorders (2, 3) . Here, we show that a similar diversification exists for the enzymatic sources of AA coupled to prostaglandin production, which extend beyond PLA 2 cleavage of phospholipids to include MAGL hydrolysis of the endocannabinoid 2-AG. This upstream branch point demarcates the anatomy of prostaglandin signaling in vivo, with MAGL exerting principal control over the tone and overall abundance of AA and prostaglandins in the brain and select peripheral tissues under both basal and inflammatory states. This discovery has translational implications in that we, and others, have found that neuroinflammatory prostaglandins derive in large part from COX1 (2, 20) , which also produces these signaling lipids in the gut to protect against gastrointestinal damage (8) . That cPLA 2 , rather than MAGL, provides the AA for prostaglandin biosynthesis in the gut suggests that MAGL inhibitors should avoid the gastrointestinal toxicity observed with COX1 inhibitors, a premise supported by our data ( fig. S9 ). MAGL inhibitors, on the other hand, have been shown to downregulate CB1 receptors in specific brain regions and to cause mild physical dependence after chronic treatment at high doses (12) . These adaptations will need to be considered when judging the translational potential of MAGL as a target for neuroinflammatory and neurodegenerative disorders.
